Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0QF2W
|
|||
| Former ID |
DIB002390
|
|||
| Drug Name |
AGTC-0106
|
|||
| Synonyms |
Alpha-1 antitrypsin deficiency gene therapy, AGTC; RAAV1-CB-hAAT; Gene therapy (alpha-1 antitrypsin deficiency), Applied Genetic Technologies
Click to Show/Hide
|
|||
| Indication | Alpha-1 antitrypsin deficiency [ICD-11: 5C5A; ICD-10: E88.0, M79.3; ICD-9: 273.4] | Phase 2 | [1] | |
| Company |
Agtc; applied genetic technologies
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Alpha-1-antitrypsin (SERPINA1) | Target Info | Modulator | [2] |
| KEGG Pathway | Complement and coagulation cascades | |||
| NetPath Pathway | IL6 Signaling Pathway | |||
| Panther Pathway | Blood coagulation | |||
| Pathway Interaction Database | p73 transcription factor network | |||
| FOXA1 transcription factor network | ||||
| Reactome | Platelet degranulation | |||
| COPII (Coat Protein 2) Mediated Vesicle Transport | ||||
| Cargo concentration in the ER | ||||
| WikiPathways | Complement and Coagulation Cascades | |||
| NRF2 pathway | ||||
| Nuclear Receptors Meta-Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01054339) Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin Deficiency. U.S. National Institutes of Health. | |||
| REF 2 | First gene therapy nears landmark European market authorization. Nat Biotechnol. 2012 Sep;30(9):807-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.